Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Subjects participating in this study will be respectively randomised (1:2:2:2) to receive either:
* placebo or
* escitalopram 20 mg/day or
* escitalopram 20 mg/day in combination with gaboxadol 5 mg/day or
* escitalopram 20 mg/day in combination with gaboxadol 10 mg/day
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical Diagnosis of MDD according to DSM-IV-TR criteria:
With reported duration of the current major depressive episode of at least 3 months
With MADRS total score of at least 30
You may not be if
The patient has 1 or more of the following:
Any current psychiatric disorder other than MDD as defined in the DSM-IV-TR
Current or past history of: manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR
Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR
Presence or history of a clinically significant neurological disorder (including epilepsy)
Any Axis II disorder that might compromise the study
Previous use of hallucinogenic drug
The patient has a significant risk of suicide according to the investigator's opinion, or has a score \>=5 on item 10 (suicidal thoughts) of the MADRS, or has made a suicide attempt in the previous 12 months.
Clareo Health | Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
